Ipamorelin (5 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (Ipamorelin, 5 mg each):
  • 8 weeks: approximately 2 vials required
  • 12 weeks: approximately 4 vials required
  • 16 weeks: approximately 5 vials required
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 6 mL — 1 bottle required (10 mL each)
  • 12 weeks (4 vials): 12 mL — 2 bottles required (10 mL each)
  • 16 weeks (5 vials): 15 mL — 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

Ipamorelin 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 100–250 mcg once daily (gradual titration recommended).
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and follow the exact formulation’s validated use-by period.

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor^[1][2]. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it one of the safer GH secretagogues with minimal off-target hormonal effects^[1][3]. This educational protocol presents a once-daily subcutaneous approach using practical dilution for precise insulin-syringe measurements.

This strength-specific ipamorelin dosage guide explains how a 5 mg vial, a 3 mL final volume, and U-100 syringe units relate to the unchanged calculation chart above. The existing dose rows remain an educational protocol framework; they are not an FDA-approved regimen and were not tested as a complete schedule in the human clinical trial literature summarized below.

• Compound: Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that binds the growth hormone secretagogue receptor, also called GHSR-1a.^[1][2]
• 5 mg vial math: Reconstituting the ipamorelin vial to 3.0 mL produces approximately 1.67 mg/mL. One U-100 unit equals 0.01 mL and contains approximately 16.7 mcg at this concentration.
• Schedule status: The displayed 100–250 mcg dose progression, once-daily frequency, timing, and cycle length are preserved exactly as previously published. This release does not change any schedule value.
• Human evidence: Published human ipamorelin research used intravenous administration, including a healthy-volunteer pharmacology study and a postoperative-ileus trial. It did not validate this subcutaneous protocol.^[4][6][14]
• Regulatory context: Ipamorelin is not FDA-approved. FDA materials identify safety and quality concerns for compounded ipamorelin acetate, including insufficient safety information for proposed subcutaneous use.^[11][12]

The ipamorelin dosage chart keeps peptide mass, syringe units, mL, frequency, and duration together. For this 5 mg vial, divide 5 mg by 3 mL to obtain about 1.67 mg/mL. Because one U-100 syringe unit is 0.01 mL, each unit contains about 0.0167 mg, or 16.7 mcg per unit.

That concentration converts the existing rows as follows: 100 mcg is 6 units (0.06 mL), 150 mcg is 9 units (0.09 mL), 200 mcg is 12 units (0.12 mL), and 250 mcg is 15 units (0.15 mL). These are rounded volume markings. Syringe units are not peptide IU, and the 5 mg vial strength does not independently determine a dose.

A peptide dosage calculator can check the arithmetic by using vial amount, final liquid volume, and target mass. The site’s ipamorelin dosage calculator does not select a route, timing, frequency, dose, or protocol. A calculation may be internally correct without being clinically validated.

A 5 mg vial and a 10 mg vial contain the same peptide at different total amounts. When each is reconstituted to 3 mL, the 5 mg vial makes about 1.67 mg/mL, while the 10 mg vial makes about 3.33 mg/mL. A given peptide dose therefore occupies twice as much liquid in the 5 mg preparation as in the 10 mg preparation.

For example, 100 mcg is 6 syringe units from this 5 mg vial but approximately 3 units from a 10 mg vial prepared to the same 3 mL final volume. The 5 mg vial may make smaller mass changes easier to see on a U-100 syringe; the 10 mg vial contains more total peptide. Neither vial strength changes the pharmacology, creates a recommended dose, or proves a different cycle length.

The separate 10 mg ipamorelin dosage protocol retains its own concentration and syringe-unit calculations. Readers should not copy units between strengths without recalculating the concentration.

The most informative healthy-volunteer study enrolled eight men at each of five intravenous infusion levels. Pharmacokinetic-pharmacodynamic modeling of ipamorelin found dose-proportional exposure, an estimated terminal half-life of about two hours, and a single growth hormone peak at approximately 0.67 hours. Because this was an intravenous infusion study, it does not establish a subcutaneous injection dose, a bedtime schedule, or a 5mg vial protocol.^[4]

A randomized phase 2 clinical trial later evaluated the ghrelin mimetic ipamorelin after bowel resection. The report used intravenous weight-based dosing for up to seven days and did not find a statistically significant difference in its primary efficacy endpoint. The registered study describes the trial arms and monitored surgical population. It was not a trial of muscle growth, fat loss, body composition, athletic recovery, or long-term peptide cycles.^[6][14]

Preclinical studies helped characterize ipamorelin as a growth hormone secretagogue and explored growth, gastrointestinal motility, and repeated exposure in animals.^{[2][3][18][19][20]} Those findings may support mechanism research, but animal dose data cannot establish the safety and efficacy of ipamorelin for human use.

Published sleep research confirms that endogenous growth hormone release is pulsatile and often linked with nocturnal sleep, but that physiology does not validate a specific injected peptide regimen or show that bedtime administration improves outcomes.^[5]

Ipamorelin binds GHSR-1a, the growth hormone secretagogue receptor, rather than acting as growth hormone itself. Receptor activation can signal the pituitary gland to release its own growth hormone. Early preclinical work described the compound as a selective growth hormone secretagogue because it produced GH release with less ACTH and cortisol activity than comparator secretagogues in those experimental models.^[2]

The human infusion study documented a short-lived pulse of growth hormone after intravenous ipamorelin.^[4] It did not show that repeated subcutaneous injection improves body composition, lean muscle, sleep, fat metabolism, or recovery. A hormone signal is not the same as a demonstrated patient outcome.

Growth hormone-releasing hormone analogs and ghrelin-receptor agonists use different receptors. This is why CJC-1295 and ipamorelin are not interchangeable and why a CJC-1295 dosage protocol cannot be copied into a standalone ipamorelin peptide page. Combination or blend pages require their own vial composition, reconstitution, and calculation review.

Human exposure data are limited and do not provide a long-term safety database for repeated subcutaneous use. The postoperative clinical trial reported adverse events in a monitored surgical population, but its intravenous route and short duration limit generalization to community peptide protocols.^[6]

FDA’s compounding-safety material states that ipamorelin acetate may present immunogenicity and impurity risks. The agency’s 2024 briefing document also reviews nonclinical signals, the available human studies, submitted dosing information, and the lack of an approved drug product containing ipamorelin.^[11][12]

Claims about fat loss, muscle growth, anti-aging effects, or improved body composition should be separated from established evidence. Product identity, purity, aggregation, sterility, and endotoxin burden can alter risk independently of the nominal dose. Recent sports-medicine reviews describe these evidence and quality gaps and caution against treating performance-enhancing peptide use as established care.^[16][17]

Athletic rules are a separate issue from clinical safety. The World Anti-Doping Agency lists ipamorelin among growth hormone secretagogues prohibited at all times. Competitive athletes should verify the current list and their exposure risks.^[15]

The four reconstitution steps in the dosage chart remain unchanged: draw 3 mL of bacteriostatic water, inject it slowly down the vial wall, gently swirl or roll without vigorous shaking, then label and refrigerate at 2–8 °C while protecting the vial from light.

Peptide stability depends on formulation, container, temperature, moisture, light, diluent, and sterility controls. General peptide-handling guidance supports minimizing repeated temperature cycling, contamination, and unnecessary agitation.^[10] A universal discard period cannot be inferred from the 5 mg vial strength. Follow the product label and lot documentation for any validated storage or discard interval.

The Pure Lab Peptides source identifies the 5 mg product and bottle provenance; it is not the scientific basis for the ipamorelin doses or evidence claims on this page.^[13]

The existing chart specifies a subcutaneous route. General injection resources recommend clean hands and a clean surface, a new sterile syringe for every injection, an alcohol-cleaned vial stopper and skin site, systematic site rotation, and immediate disposal in an approved sharps container.^[7][8][9]

• Verify the vial strength and 3 mL final volume before using any syringe units from the chart.
• Read a U-100 syringe at eye level and remove visible air bubbles before confirming the final mL.
• Use the calculated liquid volume for the intended mass; never treat syringe units as peptide IU.
• Rotate sites and avoid bruised, scarred, inflamed, or otherwise unsuitable areas.^[7][9]
• Never reuse needles or syringes, and never place loose sharps in household recycling.^[8]

These are handling and measurement checks. They do not select a dose or validate the schedule.

What concentration does a 5 mg ipamorelin vial make with 3 mL?

Five milligrams divided by 3 mL equals approximately 1.67 mg/mL. At that concentration, one U-100 syringe unit contains about 16.7 mcg. This is concentration math, not a dose recommendation.

How do you calculate ipamorelin syringe units?

First calculate concentration from vial mass divided by final volume. Then divide the target mass by that concentration to obtain mL and multiply the mL by 100 for U-100 syringe units. Recalculate whenever vial strength or final volume changes.

Does a 5 mg vial require a different dosage protocol than a 10 mg vial?

No. Vial strength changes total available peptide and concentration, not the pharmacologic dose by itself. The same mass occupies a different liquid volume when the concentrations differ.

What ipamorelin dose was studied in humans?

Human studies used intravenous administration. Healthy volunteers received five infusion levels, and a phase 2 postoperative trial used intravenous weight-based arms. Neither study validated this page’s subcutaneous schedule.^[4][6]

Is ipamorelin FDA-approved?

No. Ipamorelin is not FDA-approved, and FDA has published concerns about compounded ipamorelin acetate and the lack of sufficient safety information for proposed subcutaneous use.^[11][12]

Is ipamorelin the same as CJC-1295?

No. Ipamorelin is a ghrelin-receptor agonist, while CJC-1295 is a GHRH analog. Ipamorelin and CJC-1295 therefore require separate evidence and calculation checks even when discussed together.

How should reconstituted ipamorelin be stored?

The existing protocol instructs refrigeration at 2–8 °C with protection from light. A verified use-by period must come from the specific product and lot documentation, not from vial strength alone.^[10]

This page separates calculation guidance from evidence claims. The displayed schedule is preserved as an educational calculation framework and is not an approved standard of care, a treatment recommendation, or proof of safety or efficacy.

• 1
  Translational Andrology and Urology (PMC): Review of growth hormone secretagogues and body-composition evidence limits

  View Source
• 2
  European Journal of Endocrinology (PubMed): Ipamorelin, the first selective growth hormone secretagogue

  View Source
• 3
  Endocrine research (PubMed): Chronic ipamorelin exposure and growth-related outcomes in rats

  View Source
• 4
  Pharmaceutical Research (PubMed): Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy volunteers

  View Source
• 5
  Journal of Clinical Endocrinology & Metabolism (PubMed): Growth hormone secretory episodes and sleep stages in healthy men

  View Source
• 6
  International Journal of Colorectal Disease (PubMed): Randomized proof-of-concept study of intravenous ipamorelin after bowel resection

  View Source
• 7
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 8
  NCBI Bookshelf: Best practices for injection preparation, asepsis, administration, and sharps disposal

  View Source
• 9
  Pharmacologic considerations (PMC): Subcutaneous drug injection and site-rotation considerations

  View Source
• 10
  NIBSC: Peptide handling, dissolution, and storage guidance

  View Source
• 11
  U.S. Food and Drug Administration: Safety risks associated with certain bulk drug substances used in compounding

  View Source
• 12
  U.S. Food and Drug Administration: 2024 Pharmacy Compounding Advisory Committee briefing document for ipamorelin

  View Source
• 13
  Pure Lab Peptides: Ipamorelin 5 mg bottle identification and product provenance

  View Source
• 14
  ClinicalTrials.gov: NCT01280344: intravenous ipamorelin for postoperative ileus

  View Source
• 15
  World Anti-Doping Agency: 2026 Prohibited List, growth hormone secretagogues including ipamorelin

  View Source
• 16
  Sports medicine review (PubMed): Performance-enhancing peptides: evidence, risk, and regulatory considerations

  View Source
• 17
  Clinical sports medicine review (PubMed): Peptide use in sport and limitations of current evidence

  View Source
• 18
  Neurogastroenterology & Motility (PubMed): Ipamorelin and gastric emptying in an animal model

  View Source
• 19
  Experimental animal research (PubMed): Ipamorelin in a rodent postoperative-ileus model

  View Source
• 20
  Growth-hormone research (PubMed): Repeated ipamorelin exposure and growth-hormone responses in rats

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.